Analyst Research

Report Title Price
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Spectrum Pharmaceuticals Inc Issues FY 2013 Revenue Guidance Below Analysts' Estimates


Friday, 15 Mar 2013 03:30pm EDT 

Spectrum Pharmaceuticals Inc announced that for fiscal 2013, it expects revenues in the range of $160 to $180 million. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenue of $253 million for fiscal 2013. 

Company Quote

8.15
0.16 +2.00%
26 Aug 2014